ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0699

T Cell Subset Analysis in Patients with Large-Vessel Vasculitis
Abstract Number: 0700

A Population-Based Study of Vasculitis Among Farmers and Urban Residents in Alberta
Abstract Number: 0701

Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study
Abstract Number: 0702

Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study
Abstract Number: 0703

Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis
Abstract Number: 0704

Clinical Characteristics and Outcomes in Patients Found to Have Clinically Isolated Aortitis After Aortic Aneurysm Repair: A Single-Center Experience
Abstract Number: 0705

Sleep Disturbances in Patients with Vasculitis: Results of the Vasculitis Patient-Powered Research Network Sleep Study (SleepVasc)
Abstract Number: 0706

Aortitis and Periaortitis Spectrum in 135 Patients from a Single Referral Centre
Abstract Number: 0707

Prevalence and Distribution of Vascular Calcifications at CT Scan in Patients with Large Vessel Vasculitis and Patients with Lymphoma: A Matched Cross-sectional Study
Abstract Number: 0708

NFKB1 and NFKBIA: Relevant Players in the Pathogenesis of IgA Vasculitis?
Abstract Number: 0709

Survival of Adults with IgA Vasculitis
Abstract Number: 0710

The Association of IgA Vasculitis and Malignancy in Adults: A Systematic Review
Abstract Number: 0711

IgA Vasculitis in a Diverse Adult Patient Population
Abstract Number: 0712

Clinical and Histologic Prognostic Factors of Renal Progression in Adults with IgA Vasculitis
Abstract Number: 0713

IgG4-Related Disease as a Potencial Etiology of Idiopathic Constrictive Pericarditis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].